NorthStar's expanded and aligned executive team brings global commercialization and financial expertise to lead the company as a fully sustainable organization.

· Appointed Stephen Merrick as President and Chief Executive Officer. Mr. Merrick has been with NorthStar since March 2016, initially in the role of Chief Operating Officer and later as President and Chief Operating Officer. He possesses broad executive experience in the pharmaceutical industry at Bristol-Myers Squibb, Mallinckrodt and Baxter Healthcare, and expertise in product development and driving domestic and global market demand. Mr. Merrick served as Vice President, International Marketing for Baxter International's Hospital Products business and prior to that, he was Senior Vice President and President - International Commercial Operations for Mallinckrodt Pharmaceuticals. He previously worked in management at Bristol-Myers Squibb for 17 years in positions of increasing responsibility and began his corporate career with Eli Lilly and Company.


· Appointed Paul Estrem, CPA, as Senior Vice President and Chief Financial Officer. Mr. Estrem holds financial responsibility for the operations of NorthStar and has relevant financial experience in the life science and medical technology industries. He served as CFO at Melinta Therapeutics, Inc. where he guided the company in converting from a private to public enterprise, raised more than $500 million in support of the company, assisted in product acquisitions, facilitated a merger and supported the commercial launch of multiple products. Previously, he was with Baxter International, Inc., where he held both financial and non-financial positions of increasing responsibility, including roles as divisional CFO for various divisions, CFO of Baxter's operations in Japan and serving as the Vice-President of Integration for a large acquisition. Mr. Estrem was previously a public accountant with Arthur Andersen & Co.

· Appointed Dave Wilson as Vice President, Operations. Mr. Wilson has been with NorthStar for more than three years, initially in the roles of Director of Isotope Processing and Director of Manufacturing. His expertise in creating and implementing successful operational programs in rapidly growing radiopharmaceutical businesses provides a valuable resource for NorthStar. Previously he was Vice President, PET & SPECT Pharmacy Operations for Triad Isotopes, where he oversaw daily operations of its southeastern U.S. radiopharmacies and led all its PET manufacturing sites through several FDA approvals, including F-18 FDG and F-18 NaF. Prior to that, at PETNET Solutions, a Siemens company, Mr. Wilson led multi-disciplinary teams in a dynamic growth environment to establish new PET isotope manufacturing centers across the United States. He is a Board Certified Nuclear Pharmacist and holds a Bachelor of Science in Pharmacy from the St. Louis College of Pharmacy.

Molecular Imaging Homepage